Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin

N. Walach, Y. Horn

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 21 patients with histologic diagnosis of metastatic adenocarcinoma and an occult primary tumor were treated with combination chemotherapy. The regimen consisted of cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil (COMF). The overall response rate was 47.6%. Six patients (28.6%) achieved complete response (mean duration, 36.5 months) and four patients (19%) achieved partial response (mean duration, 7.7 months). Toxicity was manageable and occurred in 14 patients (67%). The COMF combination serves as a broad-spectrum chemotherapy regimen in adenocarcinoma of unknown primary origin.

Original languageEnglish
Pages (from-to)605-607
Number of pages3
JournalCancer Treatment Reports
Volume71
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin'. Together they form a unique fingerprint.

Cite this